Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancerS.N. Westin, Robert L. Coleman, Rhys Williams et al.|Annals of Oncology|2017Cited by 16